Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

Remy B. Verheijen; Huixin Yu; Jan H M Schellens; Jos H Beijnen; Neeltje Steeghs; Alwin D R Huitema

doi:10.1002/cpt.787

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

Remy B. Verheijen, Huixin Yu, Jan H M Schellens, Jos H Beijnen, Neeltje Steeghs, Alwin D R Huitema

Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
University Medical Center Utrecht

Research output: Contribution to journal › Review article › peer-review

Abstract

Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable and clear relationships exist between exposure and treatment outcomes, fixed dosing is still standard practice. This review aims to summarize the available clinical pharmacokinetic and pharmacodynamic data into practical guidelines for individualized dosing of KIs through therapeutic drug monitoring (TDM). Additionally, we provide an overview of prospective TDM trials and discuss the future steps needed for further implementation of TDM of KIs.

Original language	English
Pages (from-to)	765-776
Number of pages	12
Journal	Clinical Pharmacology and Therapeutics
Volume	102
Issue number	5
DOIs	https://doi.org/10.1002/cpt.787
Publication status	Published - Nov 2017

Keywords

Dose-Response Relationship, Drug
Drug Monitoring
Humans
Medical Oncology
Neoplasms
Practice Guidelines as Topic
Prospective Studies
Protein Kinase Inhibitors

Access to Document

10.1002/cpt.787

Verheijen_et_al-2017-Clinical_Pharmacology_&_TherapeuticsFinal published version, 325 KB

Cite this

@article{5381b39e145149c38cf947c418d88b69,

title = "Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology",

abstract = "Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable and clear relationships exist between exposure and treatment outcomes, fixed dosing is still standard practice. This review aims to summarize the available clinical pharmacokinetic and pharmacodynamic data into practical guidelines for individualized dosing of KIs through therapeutic drug monitoring (TDM). Additionally, we provide an overview of prospective TDM trials and discuss the future steps needed for further implementation of TDM of KIs.",

keywords = "Dose-Response Relationship, Drug, Drug Monitoring, Humans, Medical Oncology, Neoplasms, Practice Guidelines as Topic, Prospective Studies, Protein Kinase Inhibitors",

author = "Verheijen, {Remy B.} and Huixin Yu and Schellens, {Jan H M} and Beijnen, {Jos H} and Neeltje Steeghs and Huitema, {Alwin D R}",

note = "{\textcopyright} 2017 The Authors Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.",

year = "2017",

month = nov,

doi = "10.1002/cpt.787",

language = "English",

volume = "102",

pages = "765--776",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Wiley-Blackwell",

number = "5",

}

TY - JOUR

T1 - Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

AU - Verheijen, Remy B.

AU - Yu, Huixin

AU - Schellens, Jan H M

AU - Beijnen, Jos H

AU - Steeghs, Neeltje

AU - Huitema, Alwin D R

PY - 2017/11

Y1 - 2017/11

N2 - Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable and clear relationships exist between exposure and treatment outcomes, fixed dosing is still standard practice. This review aims to summarize the available clinical pharmacokinetic and pharmacodynamic data into practical guidelines for individualized dosing of KIs through therapeutic drug monitoring (TDM). Additionally, we provide an overview of prospective TDM trials and discuss the future steps needed for further implementation of TDM of KIs.

AB - Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable and clear relationships exist between exposure and treatment outcomes, fixed dosing is still standard practice. This review aims to summarize the available clinical pharmacokinetic and pharmacodynamic data into practical guidelines for individualized dosing of KIs through therapeutic drug monitoring (TDM). Additionally, we provide an overview of prospective TDM trials and discuss the future steps needed for further implementation of TDM of KIs.

KW - Dose-Response Relationship, Drug

KW - Drug Monitoring

KW - Humans

KW - Medical Oncology

KW - Neoplasms

KW - Practice Guidelines as Topic

KW - Prospective Studies

KW - Protein Kinase Inhibitors

U2 - 10.1002/cpt.787

DO - 10.1002/cpt.787

M3 - Review article

C2 - 28699160

SN - 0009-9236

VL - 102

SP - 765

EP - 776

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 5

ER -

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

Abstract

Keywords

Access to Document

Fingerprint

Cite this